Janux Therapeutics (JANX) Return on Capital Employed (2021 - 2026)
Janux Therapeutics (JANX) reported Return on Capital Employed of 16.42% for Q1 2026, down 549.0% year-over-year from 3.66% in Q1 2025, and down 2.92% quarter-over-quarter from 15.96% in Q4 2025.
Janux Therapeutics (JANX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 6 years of Return on Capital Employed data on file, last reported at 16.42% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 16.42%, down 549.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 16.42% (down 549.0% YoY), and the FY2025 annual result was 15.66%, down 161.0% from the prior year.
- Return on Capital Employed eased to 16.42% in Q1 2026 per JANX's latest filing, from 15.96% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 9.72% in Q2 2024 and troughed at 23.48% in Q2 2023.
- A 5-year average of 15.85% and a median of 15.16% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed plunged 1158 bps in 2022, then surged 1376 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 18.99% in 2022, then slipped by 4 bps to 19.69% in 2023, then jumped by 42 bps to 11.48% in 2024, then plunged by 39 bps to 15.96% in 2025, then fell by 3 bps to 16.42% in 2026.
- Business Quant data shows JANX's Return on Capital Employed at 16.42% in Q1 2026, 15.96% in Q4 2025, and 14.42% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Janux Therapeutics | 892.99 Mn | 892.99 Mn | - | -16.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.42% |
| Dec 31, 2025 | -15.96% |
| Sep 30, 2025 | -14.42% |
| Jun 30, 2025 | -14.20% |
| Mar 31, 2025 | -10.94% |
| Dec 31, 2024 | -11.48% |
| Sep 30, 2024 | -12.72% |
| Jun 30, 2024 | -9.72% |
| Mar 31, 2024 | -13.90% |
| Dec 31, 2023 | -19.69% |
| Sep 30, 2023 | -21.48% |
| Jun 30, 2023 | -23.48% |
| Mar 31, 2023 | -21.56% |
| Dec 31, 2022 | -18.99% |
| Sep 30, 2022 | -17.11% |
| Jun 30, 2022 | -15.16% |
| Mar 31, 2022 | -12.22% |
| Dec 31, 2021 | -8.84% |
| Sep 30, 2021 | -5.53% |